In the claims:

Kindly amend the claims as set forth below.

1. to 6. **[Cancelled]**

7. (Amended) A composition as claimed in claim 34~~Claim 6~~, wherein the cyclodextrin is hydroxypropyl-β-cyclodextrin.

8. to 14. **[Cancelled]**

15 to 19 **[Previously Cancelled]**

20. (Currently amended) A method of treating a patient in need of treatment with fexofenadine or a pharmaceutically acceptable salt thereof which comprises administering an effective amount of a composition according to ~~Claim 1~~claim 34 to a patient in need of such treatment.

21. (Currently amended) A method of treating rhinitis which comprises administering an effective amount of a composition according to ~~Claim 1~~claim 34, to a patient in need of such treatment.

22. to 27. **[Cancelled]**

28. (Currently amended) The composition as claimed in claim 35~~claim 23~~, which further comprises a gelling agent or a bioadhesive material.

29. (Previously added) The composition as claimed in claim 28, wherein the gelling agent or bioadhesive material is selected from the group consisting of pectin, alginate, starch, gellan, chitosan, and a block co-polymer.

30. (Currently amended) The composition as claimed in claim 35~~claim 1~~, which further comprises a material that provides for controlled release of the fexofenadine or a pharmaceutically acceptable salt thereof.

31. (Currently amended) A method of treating a patient in need of a treatment with fexofenadine or a pharmaceutically acceptable salt thereof, the method comprising administering an effective amount of the composition according to claim 35~~claim 23~~ to a patient in need of such treatment.

32. (Currently amended) A method of treating rhinitis, the method comprising administering an effective amount of a composition according to claim 35~~claim 23~~ to a patient in need of such treatment.

33. (Previously added) A method of treating a patient with a controlled release dose of fexofenadine or a pharmaceutically acceptable salt thereof, the method comprising administering an effective amount of a composition according to claim 30 to a patient in need of such treatment.

34. (New) A composition consisting essentially of

(i) fexofenadine or a pharmaceutically acceptable salt thereof and

(ii) a pharmaceutical excipient that increases the solubility of the fexofenadine or salt in water selected from the group consisting of a cyclodextrin, propylene glycol, and glycofurol (tetraglycol),

which composition is adapted for delivery of the fexofenadine or pharmaceutically acceptable salt thereof to the eye or nose.

35. (New) A composition comprising

(i) fexofenadine or a pharmaceutically acceptable salt thereof in an amount selected from the group consisting of 100 μg/ml to 100 mg/ml and 0.5% to 40% wt/wt and

(ii) a pharmaceutical excipient that increases the solubility of the fexofenadine or salt in water selected from the group consisting of a cyclodextrin, propylene glycol, and glycofurol (tetraglycol),

which composition is adapted for delivery of the fexofenadine or pharmaceutically acceptable salt thereof to the eye or nose.

36. (New) The composition of claim 35, wherein the cyclodextrin is hydroxypropyl-β-cyclodextrin.

37. (New) The composition of claim 35, wherein the composition further comprises an aqueous vehicle.

38. (New) The composition of claim 28, wherein the gelling agent or bioadhesive material is a polysaccharide.

39. (New) The composition of claim 29, wherein the block co-polymer is a poloaxmer.